Structure Therapeutics Inc.
GPCRStructure Therapeutics Inc. in brief
Structure Therapeutics Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $4.7 B on 20 October 2026, which makes it the 3,728th largest listed company in the world and the 1,087th largest in the USA on this site. It employs about 220 people. Its shares trade under the symbol GPCR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Structure Therapeutics Inc.
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors. These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders. By leveraging our world-class GPCR know-how, we are designing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies that target this family of receptors.
From the company's annual report filed with the US SEC: read the report
Structure Therapeutics Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- ✎Renamed Structure Therapeutics Inc.Formerly ShouTi Inc..
- 2023
- 🔔Initial public offeringFinal prospectus filed with the SEC on 6 February 2023; shares registered for exchange trading on 30 January 2023.
Events of Structure Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,081 (Oct 2026) · #1,088 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.1×
- Free cash flow yield
- -4.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -9.3%
- Liabilities / assets
- 4.3%
- Profit per employee
- $-642 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-177M | $-141M | — |
| Dec 2024 | — | — | $-158M | $-123M | — |
| Dec 2023 | — | — | $-103M | $-90M | — |
| Dec 2022 | — | — | $-53M | $-51M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-222M | $4M | $-226M | $-0.80 | — |
| Dec 2024 | $-117M | $1M | $-118M | $-0.78 | — |
| Dec 2023 | $-79M | $2M | $-82M | $-0.81 | — |
| Dec 2022 | $-46M | $0M | $-46M | $-5.51 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-145M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Sep 8, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 18, 20268-KCurrent reportShareholder vote
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportMaterial agreement · Results of operations · Other events
- Apr 23, 2026DEF 14AProxy statement
- Apr 15, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Mar 16, 20268-KCurrent reportRegulation FD disclosure · Other events
- Feb 26, 202610-KAnnual report · period to Dec 2025
Official filings of Structure Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-177 M
- Net income
- $-141 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $1.6 B
- Total liabilities
- $68 M
- Total equity
- $1.5 B
As of December-2025
Top 100 institutional investors in Structure Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Wellington Management Group LLP | 9,762,981 | +2,383,548 (+32.30%) | 4.55% | $305 M | Nov 16, 2026 |
| 2 | FMR LLC | 9,354,478 | +1,544,172 (+19.77%) | 4.36% | $293 M | Nov 10, 2026 |
| 3 | Avoro Capital Advisors LLC | 6,555,555 | 0 (0.00%) | 3.05% | $205 M | Nov 16, 2026 |
| 4 | Janus Henderson Group Ltd. | 5,070,156 | — | 2.36% | $159 M | Nov 16, 2026 |
| 5 | Deep Track Capital, LP | 5,000,000 | +259,928 (+5.48%) | 2.33% | $156 M | Nov 16, 2026 |
| 6 | Morgan Stanley | 2,816,776 | +10,136 (+0.36%) | 1.31% | $88 M | Nov 13, 2026 |
| 7 | BVF Inc/il | 2,691,426 | -675,397 (-20.06%) | 1.25% | $84 M | Nov 16, 2026 |
| 8 | RTW Investments, LP | 2,282,138 | +674,631 (+41.97%) | 1.06% | $71 M | Nov 16, 2026 |
| 9 | Baker Bros. Advisors LP | 1,432,529 | 0 (0.00%) | 0.67% | $45 M | Nov 16, 2026 |
| 10 | Orbimed Advisors LLC | 1,331,000 | -878,400 (-39.76%) | 0.62% | $42 M | Nov 16, 2026 |
| 11 | Paradigm Biocapital Advisors LP | 1,299,199 | New | 0.60% | $41 M | Nov 16, 2026 |
| 12 | Principal Financial Group Inc | 1,264,946 | -487,807 (-27.83%) | 0.59% | $40 M | Nov 2, 2026 |
| 13 | Deerfield Management Company, L.P. | 1,086,000 | 0 (0.00%) | 0.51% | $34 M | Nov 16, 2026 |
| 14 | Casdin Capital, LLC | 1,030,000 | -145,000 (-12.34%) | 0.48% | $32 M | Nov 16, 2026 |
| 15 | Logos Global Management LP | 1,000,000 | +500,000 (+100.00%) | 0.47% | $31 M | Nov 16, 2026 |
| 16 | Siren, L.L.C. | 872,967 | 0 (0.00%) | 0.41% | $27 M | Nov 12, 2026 |
| 17 | Aberdeen Group plc | 858,784 | +218,869 (+34.20%) | 0.40% | $27 M | Nov 10, 2026 |
| 18 | Capitolis Liquid Global Markets LLC | 835,000 | -206,100 (-19.80%) | 0.39% | $26 M | Nov 12, 2026 |
| 19 | Driehaus Capital Management LLC | 803,818 | -749,401 (-48.25%) | 0.37% | $25 M | Nov 16, 2026 |
| 20 | Pacific Heights Asset Management LLC | 800,000 | 0 (0.00%) | 0.37% | $25 M | Nov 3, 2026 |
| 21 | BlackRock, Inc. | 705,946 | +194,797 (+38.11%) | 0.33% | $22 M | Nov 13, 2026 |
| 22 | Rock Springs Capital Management LP | 640,317 | 0 (0.00%) | 0.30% | $20 M | Nov 16, 2026 |
| 23 | Alliancebernstein L.P. | 581,971 | -29,737 (-4.86%) | 0.27% | $18 M | Nov 16, 2026 |
| 24 | Jpmorgan Chase & Co | 546,189 | +542,205 (+13609.56%) | 0.25% | $17 M | Nov 12, 2026 |
| 25 | Blue Sparrow, LLC /DE | 473,200 | New | 0.22% | $15 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Two Sigma Investments, LP | 442,107 | +237,951 (+116.55%) | 0.21% | $14 M | Nov 16, 2026 |
| 27 | Goldman Sachs Group Inc | 431,311 | +188,521 (+77.65%) | 0.20% | $13 M | Nov 16, 2026 |
| 28 | Price T Rowe Associates Inc /MD/ | 378,228 | -467,304 (-55.27%) | 0.18% | $12 M | Nov 16, 2026 |
| 29 | Franklin Templeton Inc | 371,271 | -207,568 (-35.86%) | 0.17% | $12 M | Nov 12, 2026 |
| 30 | UBS Group AG | 332,122 | -46,864 (-12.37%) | 0.15% | $10 M | Nov 10, 2026 |
| 31 | National Bank Of Canada /fi/ | 318,545 | +102,745 (+47.61%) | 0.15% | $10 M | Nov 16, 2026 |
| 32 | NEXTBio Capital Management LP | 312,496 | 0 (0.00%) | 0.15% | $10 M | Nov 13, 2026 |
| 33 | American Century Companies Inc | 303,882 | -1,378,297 (-81.94%) | 0.14% | $10 M | Nov 12, 2026 |
| 34 | Parkman Healthcare Partners LLC | 283,763 | -201,898 (-41.57%) | 0.13% | $9 M | Nov 16, 2026 |
| 35 | HSG Holding Ltd | 266,062 | 0 (0.00%) | 0.12% | $8 M | Nov 13, 2026 |
| 36 | Catalio Capital Management, LP | 260,109 | -16,441 (-5.95%) | 0.12% | $8 M | Nov 16, 2026 |
| 37 | SEB Asset Management AB | 245,043 | 0 (0.00%) | 0.11% | $8 M | Nov 4, 2026 |
| 38 | Jane Street Group, LLC | 232,677 | New | 0.11% | $7 M | Nov 12, 2026 |
| 39 | Trexquant Investment LP | 200,230 | New | 0.09% | $6 M | Nov 16, 2026 |
| 40 | Rhenman & Partners Asset Management AB | 183,300 | +38,200 (+26.33%) | 0.09% | $6 M | Nov 12, 2026 |
| 41 | B Group, Inc. | 180,000 | +40,000 (+28.57%) | 0.08% | $6 M | Nov 16, 2026 |
| 42 | HighVista Strategies LLC | 170,193 | +39,409 (+30.13%) | 0.08% | $5 M | Nov 13, 2026 |
| 43 | Eversept Partners, LP | 155,127 | -41,175 (-20.98%) | 0.07% | $5 M | Nov 16, 2026 |
| 44 | Woodline Partners LP | 153,886 | +78 (+0.05%) | 0.07% | $5 M | Nov 16, 2026 |
| 45 | Bank Of America Corp /de/ | 149,978 | -413,444 (-73.38%) | 0.07% | $5 M | Nov 16, 2026 |
| 46 | Universal- Beteiligungs- und Servicegesellschaft mbH | 140,623 | +14,934 (+11.88%) | 0.07% | $4 M | Nov 10, 2026 |
| 47 | Susquehanna International Group, LLP | 136,435 | +14,091 (+11.52%) | 0.06% | $4 M | Nov 16, 2026 |
| 48 | Healthcare Of Ontario Pension Plan Trust Fund | 135,299 | -283,501 (-67.69%) | 0.06% | $4 M | Nov 13, 2026 |
| 49 | Jefferies Financial Group Inc. | 122,322 | +81,697 (+201.10%) | 0.06% | $4 M | Nov 5, 2026 |
| 50 | Walleye Capital LLC | 118,391 | New | 0.06% | $4 M | Nov 13, 2026 |
| 51 | Citadel Advisors LLC | 116,295 | New | 0.05% | $4 M | Nov 16, 2026 |
| 52 | D. E. Shaw & Co., Inc. | 115,300 | 0 (0.00%) | 0.05% | $4 M | Nov 16, 2026 |
| 53 | Peregrine Capital Management LLC | 114,982 | +22,753 (+24.67%) | 0.05% | $4 M | Nov 9, 2026 |
| 54 | Susquehanna Portfolio Strategies, LLC | 113,904 | -35,044 (-23.53%) | 0.05% | $4 M | Nov 16, 2026 |
| 55 | Marshall Wace, LLP | 108,366 | -159,226 (-59.50%) | 0.05% | $3 M | Nov 13, 2026 |
| 56 | Geode Capital Management, LLC | 105,636 | +8,453 (+8.70%) | 0.05% | $3 M | Nov 6, 2026 |
| 57 | Squarepoint Ops LLC | 104,907 | -20,668 (-16.46%) | 0.05% | $3 M | Nov 9, 2026 |
| 58 | Nomura Asset Management International Inc. | 96,968 | -56,151 (-36.67%) | 0.05% | $3 M | Nov 16, 2026 |
| 59 | Alps Advisors Inc | 94,499 | +22,666 (+31.55%) | 0.04% | $3 M | Nov 3, 2026 |
| 60 | State Street Corp | 92,556 | +47,927 (+107.39%) | 0.04% | $3 M | Nov 12, 2026 |
| 61 | Platinum Investment Management LTD | 90,363 | 0 (0.00%) | 0.04% | $3 M | Nov 16, 2026 |
| 62 | Qube Research & Technologies Ltd | 85,415 | -7,988 (-8.55%) | 0.04% | $3 M | Nov 13, 2026 |
| 63 | Millennium Management LLC | 80,675 | -8,893 (-9.93%) | 0.04% | $3 M | Nov 16, 2026 |
| 64 | PFM Health Sciences, LP | 66,404 | -25,146 (-27.47%) | 0.03% | $2 M | Nov 16, 2026 |
| 65 | HRT Financial LP | 65,055 | New | 0.03% | $2 M | Nov 13, 2026 |
| 66 | Voloridge Investment Management, LLC | 60,300 | -52,000 (-46.30%) | 0.03% | $2 M | Nov 16, 2026 |
| 67 | Burkehill Global Management, LP | 60,000 | 0 (0.00%) | 0.03% | $2 M | Nov 16, 2026 |
| 68 | Buckland Partners Management Co LLC | 60,000 | +10,000 (+20.00%) | 0.03% | $2 M | Nov 13, 2026 |
| 69 | XTX Topco Ltd | 55,586 | New | 0.03% | $2 M | Nov 16, 2026 |
| 70 | Brevan Howard Capital Management LP | 51,516 | -8,820 (-14.62%) | 0.02% | $2 M | Nov 16, 2026 |
| 71 | Schonfeld Strategic Advisors LLC | 49,558 | -141,127 (-74.01%) | 0.02% | $2 M | Nov 16, 2026 |
| 72 | Bank Of Montreal /can/ | 47,473 | +4,903 (+11.52%) | 0.02% | $1 M | Nov 9, 2026 |
| 73 | DAFNA Capital Management LLC | 46,500 | 0 (0.00%) | 0.02% | $1 M | Nov 16, 2026 |
| 74 | Exchange Traded Concepts, LLC | 45,508 | +14,735 (+47.88%) | 0.02% | $1 M | Oct 28, 2026 |
| 75 | DCF Advisers, LLC | 45,000 | +12,900 (+40.19%) | 0.02% | $1 M | Nov 4, 2026 |
| 76 | Osaic Holdings, Inc. | 44,938 | +152 (+0.34%) | 0.02% | $1 M | Nov 12, 2026 |
| 77 | Mariner, LLC | 35,050 | -11,235 (-24.27%) | 0.02% | $1 M | Nov 12, 2026 |
| 78 | TrueMark Investments, LLC | 33,083 | -517 (-1.54%) | 0.02% | $1 M | Nov 5, 2026 |
| 79 | TD Asset Management Inc | 30,162 | -38,800 (-56.26%) | 0.01% | $1 M | Nov 13, 2026 |
| 80 | Cormorant Asset Management, LP | 30,000 | -45,000 (-60.00%) | 0.01% | $1 M | Nov 16, 2026 |
| 81 | Private Capital Advisors, Inc. | 29,760 | 0 (0.00%) | 0.01% | $1 M | Oct 6, 2026 |
| 82 | ADAR1 Capital Management, LLC | 27,500 | +10,000 (+57.14%) | 0.01% | $1 M | Nov 16, 2026 |
| 83 | Nomura Asset Management Co LTD | 26,949 | -5,841 (-17.81%) | 0.01% | $1 M | Nov 12, 2026 |
| 84 | EntryPoint Capital, LLC | 26,928 | +20,792 (+338.85%) | 0.01% | $1 M | Nov 13, 2026 |
| 85 | Tower Research Capital LLC (TRC) | 23,726 | +22,829 (+2545.04%) | 0.01% | $1 M | Nov 16, 2026 |
| 86 | Verition Fund Management LLC | 21,219 | -7,300 (-25.60%) | 0.01% | $1 M | Nov 13, 2026 |
| 87 | Y-Intercept (Hong Kong) Ltd | 21,050 | -6,523 (-23.66%) | 0.01% | $1 M | Oct 16, 2026 |
| 88 | Ameriprise Financial Inc | 20,368 | -210,146 (-91.16%) | 0.01% | $1 M | Nov 16, 2026 |
| 89 | Handelsbanken Fonder AB | 19,400 | 0 (0.00%) | 0.01% | $1 M | Nov 9, 2026 |
| 90 | ANTIPODES PARTNERS Ltd | 19,088 | -32,174 (-62.76%) | 0.01% | $1 M | Nov 5, 2026 |
| 91 | LPL Financial LLC | 18,667 | +4,334 (+30.24%) | 0.01% | $1 M | Nov 6, 2026 |
| 92 | Voya Investment Management LLC | 18,385 | -26,025 (-58.60%) | 0.01% | $1 M | Nov 10, 2026 |
| 93 | Flax Pond Capital, LLC | 17,688 | -55,312 (-75.77%) | 0.01% | $1 M | Nov 18, 2026 |
| 94 | Teachers Retirement System Of The State Of Kentucky | 17,297 | 0 (0.00%) | 0.01% | $1 M | Nov 10, 2026 |
| 95 | SEI Investments Co | 16,548 | +2,864 (+20.93%) | 0.01% | $1 M | Nov 10, 2026 |
| 96 | BNP Paribas Financial Markets | 14,968 | -2,813 (-15.82%) | 0.01% | $0 M | Nov 12, 2026 |
| 97 | China Universal Asset Management Co., Ltd. | 14,957 | +2,548 (+20.53%) | 0.01% | $0 M | Oct 28, 2026 |
| 98 | Stifel Financial Corp | 14,832 | -200 (-1.33%) | 0.01% | $0 M | Nov 12, 2026 |
| 99 | DNB Asset Management As | 14,633 | +3,854 (+35.75%) | 0.01% | $0 M | Nov 12, 2026 |
| 100 | Jump Financial, LLC | 14,323 | -28,335 (-66.42%) | 0.01% | $0 M | Nov 13, 2026 |
Mutual funds holding Structure Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Health Care FundWellington Management Company LLP | 3.28 M | $157 M | 1.5% | 0.41% | +13% | Jul 31, 2026 |
| 🇺🇸 Heritage FundAmerican Century Investment Management, Inc. | 967,353 | $46 M | 0.45% | 0.87% | no change | Jul 31, 2026 |
| 🇺🇸 Global Emerging Markets FundPrincipal Global Investors, LLC | 625,751 | $30 M | 0.29% | 0.40% | no change | Jul 31, 2026 |
| 🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund | 549,353 | $29 M | 0.26% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Growth Opportunities FundFidelity Management & Research Company LLC | 733,500 | $29 M | 0.34% | 0.08% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 527,900 | $25 M | 0.25% | 1.2% | +9.7% | Jul 31, 2026 |
| 🇺🇸 Janus Henderson Triton FundJanus Investment Fund | 467,112 | $25 M | 0.22% | 0.42% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 419,407 | $23 M | 0.20% | 0.19% | −67% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 414,261 | $22 M | 0.19% | 0.24% | +8.5% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 542,038 | $21 M | 0.25% | 0.40% | −4.0% | May 31, 2026 |
| 🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC | 540,000 | $21 M | 0.25% | 0.37% | −13% | May 31, 2026 |
| 🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC | 433,100 | $21 M | 0.20% | 0.28% | +17% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 414,389 | $20 M | 0.19% | 0.23% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 405,606 | $19 M | 0.19% | 0.09% | −30% | Jul 31, 2026 |
| 🇺🇸 Aggressive Growth PortfolioPacific Heights Asset Management, LLC | 400,000 | $19 M | 0.19% | 3.8% | no change | Jul 31, 2026 |
| 🇺🇸 Permanent PortfolioPacific Heights Asset Management, LLC | 400,000 | $19 M | 0.19% | 0.27% | no change | Jul 31, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 301,239 | $16 M | 0.14% | 1.2% | +81% | Jun 30, 2026 |
| 🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC | 300,525 | $16 M | 0.14% | <0.01% | −62% | Jun 30, 2026 |
| 🇺🇸 SmallCap FundPrincipal Global Investors, LLC | 287,100 | $14 M | 0.13% | 0.66% | −4.1% | Jul 31, 2026 |
| 🇺🇸 Janus Henderson Venture FundJanus Investment Fund | 252,725 | $14 M | 0.12% | 0.37% | new | Jun 30, 2026 |
| 🇸🇪 SEB LäkemedelsfondSEB Funds AB | 245,043 | $13 M | 0.11% | 0.73% | no change | Jun 30, 2026 |
| 🇺🇸 Focused Dynamic Growth FundAmerican Century Growth Funds, Inc. | 263,026 | $13 M | 0.12% | 0.63% | −18% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC | 248,605 | $12 M | 0.12% | 0.25% | −3.4% | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC | 216,800 | $12 M | 0.10% | 0.04% | −13% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 207,816 | $11 M | 0.10% | 0.08% | −0.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 228,000 | $11 M | 0.11% | 0.35% | −19% | Jul 31, 2026 |
| 🇺🇸 Fidelity FundFidelity Management & Research Company LLC | 197,200 | $11 M | 0.09% | 0.12% | new | Jun 30, 2026 |
| 🇺🇸 Principal Capital Appreciation FundPrincipal Global Investors, LLC | 211,327 | $10 M | 0.10% | 0.26% | −28% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 207,912 | $10 M | 0.10% | 0.22% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Puritan FundFidelity Management & Research Company LLC | 244,500 | $10 M | 0.11% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 abrdn World Healthcare Fundabrdn Inc. | 176,459 | $9 M | 0.08% | 1.7% | +66% | Jun 30, 2026 |
| 🇺🇸 The Hartford Growth Opportunities FundHartford Funds Management Company, LLC | 195,389 | $9 M | 0.09% | 0.14% | −0.4% | Jul 31, 2026 |
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 230,777 | $9 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 162,217 | $9 M | 0.08% | 1.3% | +36% | Jun 30, 2026 |
| 🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc. | 178,989 | $9 M | 0.08% | 0.35% | −3.4% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 147,713 | $8 M | 0.07% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P. | 142,364 | $8 M | 0.07% | 0.24% | −17% | Jun 30, 2026 |
| 🇺🇸 AB Discovery Growth Fund, Inc.AllianceBernstein L.P. | 138,229 | $7 M | 0.06% | 0.26% | −15% | Jun 30, 2026 |
| 🇺🇸 Driehaus Small Cap Growth FundDriehaus Capital Management LLC | 137,401 | $7 M | 0.06% | 0.46% | +11% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC | 183,200 | $7 M | 0.09% | <0.01% | +4.5% | May 31, 2026 |
| 🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC | 126,600 | $7 M | 0.06% | 0.02% | −21% | Jun 30, 2026 |
| 🇺🇸 Mid Cap Growth FundJohn Hancock Investment Management LLC | 124,970 | $7 M | 0.06% | 0.50% | −4.9% | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 136,424 | $7 M | 0.06% | 0.57% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Opportunistic Insights FundFidelity Management & Research Company LLC | 117,800 | $6 M | 0.05% | 0.04% | −13% | Jun 30, 2026 |
| 🇺🇸 VIP Growth Opportunities PortfolioFidelity Management & Research Company LLC | 102,200 | $5 M | 0.05% | 0.10% | −9.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity U.S. Equity Central FundFidelity Management & Research Company LLC | 100,000 | $5 M | 0.05% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Optimum Small-Mid Cap Growth FundDelaware Management Company | 95,119 | $5 M | 0.04% | 0.54% | +186% | Jun 30, 2026 |
| 🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC | 95,000 | $5 M | 0.04% | 0.44% | −10% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC | 98,200 | $5 M | 0.05% | 0.30% | +44% | Jul 31, 2026 |
| 🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC | 84,699 | $5 M | 0.04% | 0.76% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Mid Cap Growth TrustJohn Hancock Variable Trust Advisers LLC | 82,492 | $4 M | 0.04% | 0.50% | +11% | Jun 30, 2026 |
| 🇺🇸 LVIP American Century Capital Appreciation FundLincoln Financial Investments Corporation | 80,497 | $4 M | 0.04% | 0.91% | +26% | Jun 30, 2026 |
| 🇺🇸 SA Wellington Capital Appreciation PortfolioSunAmerica Asset Management, LLC | 74,187 | $4 M | 0.03% | 0.15% | +2.1% | Jun 30, 2026 |
| 🇺🇸 The Hartford Healthcare FundHartford Funds Management Company, LLC | 79,359 | $4 M | 0.04% | 0.49% | +10% | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Small Cap FundFidelity Management & Research Company LLC | 96,300 | $4 M | 0.04% | 0.16% | no change | May 31, 2026 |
| 🇺🇸 The Hartford Small Company FundHartford Funds Management Company, LLC | 72,884 | $4 M | 0.03% | 0.52% | −2.3% | Jul 31, 2026 |
| 🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC | 63,742 | $3 M | 0.03% | <0.01% | −62% | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 58,000 | $3 M | 0.03% | 0.41% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 75,523 | $3 M | 0.04% | <0.01% | +38% | May 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 73,020 | $3 M | 0.03% | 1.8% | +35% | May 31, 2026 |
| 🇺🇸 Brighthouse/Wellington Large Cap Research PortfolioBrighthouse Investment Advisers, LLC | 52,971 | $3 M | 0.02% | 0.11% | −8.3% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 52,666 | $3 M | 0.02% | 0.13% | +0.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC | 57,300 | $3 M | 0.03% | 0.20% | +57% | Jul 31, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 65,052 | $3 M | 0.03% | <0.01% | −1.3% | May 31, 2026 |
| 🇺🇸 Hartford Small Company HLS FundHartford Funds Management Company, LLC | 47,674 | $3 M | 0.02% | 0.54% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Growth Stock PortfolioMason Street Advisors, LLC | 47,654 | $3 M | 0.02% | 0.28% | no change | Jun 30, 2026 |
| 🇺🇸 American Century Focused Dynamic Growth ETFAmerican Century ETF Trust | 59,428 | $2 M | 0.03% | 0.57% | +4.2% | May 31, 2026 |
| 🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC | 47,095 | $2 M | 0.02% | 0.15% | +17% | Jul 31, 2026 |
| 🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC | 42,027 | $2 M | 0.02% | 0.83% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Diversified Stock FundFidelity Destiny Portfolios | 41,600 | $2 M | 0.02% | 0.05% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 46,188 | $2 M | 0.02% | 0.09% | −4.8% | Jul 31, 2026 |
| 🇺🇸 Allspring Small Company Growth FundAllspring Funds Management, LLC | 42,632 | $2 M | 0.02% | 0.40% | −1.2% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 51,200 | $2 M | 0.02% | <0.01% | −13% | May 31, 2026 |
| 🇺🇸 State Street SPDR S&P Emerging Markets Small Cap ETFSSGA Funds Management, Inc. | 35,893 | $2 M | 0.02% | 0.26% | −6.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 47,468 | $2 M | 0.02% | <0.01% | +21% | May 31, 2026 |
| 🇺🇸 Hartford Small Cap Growth HLS FundHartford Funds Management Company, LLC | 34,536 | $2 M | 0.02% | 0.28% | no change | Jun 30, 2026 |
| 🇺🇸 JNL Multi-Manager Small Cap Growth FundJackson National Asset Management, LLC | 33,631 | $2 M | 0.02% | 0.07% | +13% | Jun 30, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 33,261 | $2 M | 0.02% | 0.08% | −4.3% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P. | 33,101 | $2 M | 0.02% | 0.21% | +27% | Jun 30, 2026 |
| 🇺🇸 MassMutual Small Cap Growth Equity FundMML Investment Advisers, LLC | 32,929 | $2 M | 0.02% | 0.24% | +3.7% | Jun 30, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 41,403 | $2 M | 0.02% | 0.20% | −17% | May 31, 2026 |
| 🇺🇸 Small Cap Stock TrustJohn Hancock Variable Trust Advisers LLC | 30,081 | $2 M | 0.01% | 0.54% | −1.8% | Jun 30, 2026 |
| 🇺🇸 Column Small Cap Select FundTrust for Professional Managers | 36,453 | $1 M | 0.02% | 0.08% | no change | May 31, 2026 |
| 🇺🇸 SmallCap AccountPrincipal Global Investors, LLC | 26,300 | $1 M | 0.01% | 0.71% | −1.1% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 25,918 | $1 M | 0.01% | 0.19% | −67% | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 23,797 | $1 M | 0.01% | 0.09% | +563% | Jun 30, 2026 |
| 🇺🇸 VIP Stock Selector PortfolioFidelity Management & Research Company LLC | 21,800 | $1 M | 0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB | 19,400 | $1 M | <0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 25,785 | $1 M | 0.01% | 0.14% | −6.5% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO International Index FundFidelity Management & Research Company LLC | 20,385 | $1 M | <0.01% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Wellington Balanced PortfolioBrighthouse Investment Advisers, LLC | 17,717 | $1 M | <0.01% | 0.07% | +1.2% | Jun 30, 2026 |
| 🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc. | 17,480 | $1 M | <0.01% | 0.37% | no change | Jun 30, 2026 |
| 🇺🇸 Principal Capital Appreciation AccountPrincipal Global Investors, LLC | 17,129 | $1 M | <0.01% | 0.35% | +34% | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Series Growth Opportunities FundFidelity Management & Research Company LLC | 22,800 | $1 M | 0.01% | 0.08% | −21% | May 31, 2026 |
| 🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc. | 16,316 | $1 M | <0.01% | 0.31% | no change | Jun 30, 2026 |
| 🇺🇸 Empower Small Cap Growth FundEmpower Capital Management, LLC | 15,729 | $1 M | <0.01% | 0.32% | −8.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 20,734 | $1 M | <0.01% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 LVIP American Century Select Mid Cap Managed Volatility FundLincoln Financial Investments Corporation | 14,900 | $1 M | <0.01% | 0.17% | +25% | Jun 30, 2026 |
| 🇺🇸 The Hartford Small Cap Growth FundHartford Funds Management Company, LLC | 15,161 | $1 M | <0.01% | 0.26% | −13% | Jul 31, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 13,328 | $1 M | <0.01% | 0.07% | −27% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Structure Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Crespo Blas CollCHIEF MEDICAL OFFICER | Conversion10b5-1 plan | -12,024 | — | — | 258,228 | Form 4 |
| filed | Crespo Blas CollCHIEF MEDICAL OFFICER | Shares withheld for tax10b5-1 plan | -10,626 | $11.67 | $124 K | 270,252 | Form 4 |
| filed | Xichen LinCHIEF SCIENTIFIC OFFICER | Option exercise10b5-1 plan | +17,817 | $0.340 | $6 K | 246,777 | Form 4 |
| filed | Xichen LinCHIEF SCIENTIFIC OFFICER | Conversion10b5-1 plan | -17,817 | — | — | 228,960 | Form 4 |
| filed | Xichen LinCHIEF SCIENTIFIC OFFICER | Option exercise10b5-1 plan | +11,817 | $0.340 | $4 K | 240,777 | Form 4 |
| filed | Xichen LinCHIEF SCIENTIFIC OFFICER | Conversion10b5-1 plan | -11,817 | — | — | 228,960 | Form 4 |
| filed | John Joseph BerriosChief Commercial Officer | Grant or award | +140,766 | — | — | 140,766 | Form 4 |
| filed | Xichen LinCHIEF SCIENTIFIC OFFICER | Option exercise10b5-1 plan | +11,817 | $0.340 | $4 K | 240,777 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Structure Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1 split
Trading halts
- 2025-12-08 15:17 UTC, code LUDP, resumed 15:22 UTC
- 2025-12-08 15:03 UTC, code LUDP, resumed 15:08 UTC
- 2025-12-08 14:40 UTC, code LUDP, resumed 14:45 UTC
- 2025-12-08 14:33 UTC, code LUDP, resumed 14:38 UTC
Fails to deliver
- : 42,724 shares at $22.01
- : 3,299 shares at $22.31
- : 912 shares at $23.91
- : 30 shares at $25.67
- : 2,000 shares at $28.98
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Structure Therapeutics Inc. scorecard#
Passes 1 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 20, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-4.8%Free cash flow is -4.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.80 vs -0.78Diluted EPS -0.80 in fiscal 2025 against -0.78 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$141 MNet income -$141 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-11.9%-11.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities24.8×Current ratio 24.82 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year12.5%Diluted shares up 12.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Structure Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Research and development | 225+107%— | 109+55.2%— | 70+93.7%— | 36—— | |
| General and administrative | 62+24.6%— | 49+51.2%— | 33+99.6%— | 16—— | |
| Operating expenses | 177+11.6%— | 158+54.0%— | 103+95.5%— | 53—— | |
| Operating income | −177—— | −158—— | −103—— | −53—— | |
| Income before tax | −141—— | −122—— | −89—— | −51—— | |
| Income tax | 0.5+66.1%— | 0.3+31.4%— | 0.2+1288%— | 0.0—— | |
| Net income including minority interests | −141—— | −123—— | −90—— | −51—— | |
| Net income attributable to shareholders | −141—— | −123—— | −90—— | −51—— | |
| Earnings per share, basic | -0.80—— | -0.78—— | -0.81—— | -5.51—— | |
| Earnings per share, diluted | -0.80—— | -0.78—— | -0.81—— | -5.51—— | |
| Shares, weighted average (basic) | 178+12.5%— | 158+43.3%— | 110+1050%— | 9.6—— | |
| Shares, weighted average (diluted) | 178+12.5%— | 158+43.3%— | 110+1050%— | 9.6—— | |
| Balance sheet | |||||
| Cash and cash equivalents | 800+372%50.5% | 170+30.6%18.8% | 130+397%26.9% | 26—26.7% | |
| Short-term investments | 647−9.4%40.8% | 714+112%79.0% | 338+421%70.0% | 65—66.2% | |
| Other current assets | 24+213%1.5% | 7.7+22.4%0.9% | 6.3+180%1.3% | 2.2—2.3% | |
| Current assets | 1,570+76.2%99.1% | 891+88.2%98.7% | 474+409%98.3% | 93—95.1% | |
| Property, plant and equipment | 6.7+91.3%0.4% | 3.5+7.7%0.4% | 3.2+213%0.7% | 1.0—1.1% | |
| Right-of-use (leased) assets | 6.2+76.7%0.4% | 3.5−31.2%0.4% | 5.1+1860%1.1% | 0.3—0.3% | |
| Total assets | 1,584+75.3%100% | 903+87.4%100% | 482+393%100% | 98—100% | |
| Accounts payable | 14+72.8%0.9% | 8.0+69.2%0.9% | 4.7−21.1%1.0% | 6.0—6.1% | |
| Current liabilities | 63+75.7%4.0% | 36+45.6%4.0% | 25+90.2%5.1% | 13—13.3% | |
| Lease liabilities (non-current) | 3.6+66.8%0.2% | 2.2−46.1%0.2% | 4.0—0.8% | — | |
| Total liabilities | 68+75.5%4.3% | 38+32.5%4.3% | 29+123%6.0% | 13—13.3% | |
| Retained earnings | −470—−29.7% | −329—−36.4% | −207—−42.9% | −117—−120% | |
| Shareholders' equity | 1,516+75.3%95.7% | 865+90.9%95.7% | 453—94.0% | −115—−118% | |
| Total liabilities and equity | 1,584+75.3%100% | 903+87.4%100% | 482+393%100% | 98—100% | |
| Shares outstanding | 213+23.7%— | 172+23.4%— | 139+1223%— | 11—— | |
| Cash-flow statement | |||||
| Share-based compensation | 29+54.3%— | 19+129%— | 8.2+226%— | 2.5—— | |
| Cash from operating activities | −222—— | −117—— | −79—— | −46—— | |
| Capital expenditure | −3.6—— | −1.3—— | −2.2—— | −0.2—— | |
| Cash from investing activities | 90—— | −359—— | −268—— | −62—— | |
| Shares issued | — | 515—— | — | — | |
| Cash from financing activities | 763+48.0%— | 515+14.1%— | 452+1456%— | 29—— | |
| Change in cash | 630+1486%— | 40−61.7%— | 104—— | −79—— | |
| Report | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 370+94.6%— | 135+128%— | 100+82.9%— | 67+55.1%— | 69*+105%— | 59+81.0%— | 55+148%— | 43+107%— | 33*+67.1%— | 33—— | 22—— | 21—— | 20*—— | |
| General and administrative | 81+40.4%— | 22+47.2%— | 19+18.0%— | 23+70.1%— | 18*+29.4%— | 15+11.8%— | 16+39.7%— | 13+18.6%— | 14*+23.9%— | 13—— | 11—— | 11—— | 11*—— | |
| Operating expenses | — | 156+112%— | 119+68.4%— | 89+58.7%— | — | 74+61.0%— | 70+111%— | 56+75.9%— | 47*+51.8%— | 46—— | 33—— | 32—— | 31*—— | |
| Operating income | −340—— | −156—— | −119—— | −89—— | 24*—— | −74—— | −70—— | −56—— | −47*—— | −46—— | −33—— | −32—— | −31*—— | |
| Income before tax | −293—— | −145—— | −106—— | −76—— | 33*—— | −66—— | −62—— | −47—— | −36*—— | −34—— | −26—— | −26—— | −25*—— | |
| Income tax | 0.8+59.0%— | 0.2+58.3%— | 0.2+68.3%— | 0.2+93.9%— | 0.2*+25.0%— | 0.1+17.4%— | 0.1+162%— | 0.1+238%— | 0.1*—— | 0.1—— | 0.1—— | 0.0—— | −0.3*—— | |
| Net income including minority interests | −294—— | −145*—— | −106*—— | −76—— | 33*—— | −66*—— | −62*—— | −47—— | −36*—— | −34*—— | −26*—— | −26—— | −25*—— | |
| Net income attributable to shareholders | −294—— | −145—— | −106—— | −76—— | 33*—— | −66—— | −62—— | −47—— | −36*—— | −34—— | −26—— | −26—— | −25*—— | |
| Earnings per share, basic | — | -0.66—— | -0.49—— | -0.35—— | — | -0.37—— | -0.36—— | -0.27—— | — | -0.20—— | -0.18—— | -0.19—— | — | |
| Earnings per share, diluted | — | -0.66—— | -0.49—— | -0.35—— | — | -0.37—— | -0.36—— | -0.27—— | — | -0.20—— | -0.18—— | -0.19—— | — | |
| Shares, weighted average (basic) | 219+24.6%— | 219+24.6%— | 218+26.2%— | 217+26.3%— | — | 175+2.2%— | 173+16.5%— | 172+23.1%— | — | 172—— | 148—— | 140—— | — | |
| Shares, weighted average (diluted) | 219+24.6%— | 219+24.6%— | 218+26.2%— | 217+26.3%— | — | 175+2.2%— | 173+16.5%— | 172+23.1%— | — | 172—— | 148—— | 140—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 222—16.6% | 222+116%16.6% | 273+85.4%19.1% | 316+108%21.0% | 800+372%50.5% | 103−40.2%12.4% | 147−61.5%18.0% | 152+55.5%17.6% | 170+30.6%18.8% | 172—18.4% | 382—40.3% | 98—21.4% | 130—26.9% | |
| Short-term investments | 1,018—76.3% | 1,018+46.2%76.3% | 1,070+67.3%75.1% | 1,142+66.8%75.7% | 647−9.4%40.8% | 696−6.3%83.7% | 639+17.2%78.3% | 685+102%79.0% | 714+112%79.0% | 743—79.6% | 545—57.6% | 339—74.1% | 338—70.0% | |
| Other current assets | 35—2.6% | 35+135%2.6% | 29+129%2.1% | 32+152%2.1% | 24+213%1.5% | 15+79.1%1.8% | 13+21.9%1.6% | 13−1.3%1.5% | 7.7+22.4%0.9% | 8.4—0.9% | 11—1.1% | 13—2.8% | 6.3—1.3% | |
| Current assets | 1,275—95.6% | 1,275+56.6%95.6% | 1,372+71.7%96.3% | 1,491+75.4%98.8% | 1,570+76.2%99.1% | 814−11.9%97.8% | 799−14.8%97.9% | 850+89.1%98.0% | 891+88.2%98.7% | 924—99.0% | 938—99.0% | 449—98.3% | 474—98.3% | |
| Property, plant and equipment | 10—0.8% | 10+120%0.8% | 6.3+83.1%0.4% | 6.4+80.9%0.4% | 6.7+91.3%0.4% | 4.7+25.2%0.6% | 3.5+4.3%0.4% | 3.5+12.8%0.4% | 3.5+7.7%0.4% | 3.7—0.4% | 3.3—0.4% | 3.1—0.7% | 3.2—0.7% | |
| Right-of-use (leased) assets | 6.6—0.5% | 6.6−4.2%0.5% | 6.1−19.0%0.4% | 5.6−23.3%0.4% | 6.2+76.7%0.4% | 6.9+71.2%0.8% | 7.5+75.4%0.9% | 7.3+55.7%0.8% | 3.5−31.2%0.4% | 4.0—0.4% | 4.3—0.5% | 4.7—1.0% | 5.1—1.1% | |
| Total assets | 1,334—100% | 1,334+60.4%100% | 1,425+74.6%100% | 1,508+74.0%100% | 1,584+75.3%100% | 832−10.8%100% | 816−13.8%100% | 867+89.5%100% | 903+87.4%100% | 933—100% | 947—100% | 457—100% | 482—100% | |
| Accounts payable | 34—2.5% | 34+90.4%2.5% | 11+23.8%0.8% | 7.8−10.2%0.5% | 14+72.8%0.9% | 18+111%2.1% | 9.0+307%1.1% | 8.7+33.2%1.0% | 8.0+69.2%0.9% | 8.4—0.9% | 2.2—0.2% | 6.5—1.4% | 4.7—1.0% | |
| Current liabilities | 107—8.0% | 107+86.2%8.0% | 66+69.4%4.6% | 57+56.2%3.8% | 63+75.7%4.0% | 58+72.1%6.9% | 39+72.3%4.8% | 36+54.7%4.2% | 36+45.6%4.0% | 33—3.6% | 23—2.4% | 24—5.2% | 25—5.1% | |
| Lease liabilities (non-current) | 4.1—0.3% | 4.1−5.2%0.3% | 3.6−27.5%0.3% | 3.2−37.8%0.2% | 3.6+66.8%0.2% | 4.3+60.4%0.5% | 5.0+64.6%0.6% | 5.1+45.1%0.6% | 2.2−46.1%0.2% | 2.7—0.3% | 3.0—0.3% | 3.5—0.8% | 4.0—0.8% | |
| Total liabilities | 113—8.4% | 113+81.1%8.4% | 71+60.1%5.0% | 61+45.6%4.0% | 68+75.5%4.3% | 62+70.6%7.5% | 44+70.6%5.4% | 42+52.9%4.8% | 38+32.5%4.3% | 36—3.9% | 26—2.7% | 27—6.0% | 29—6.0% | |
| Retained earnings | −797—−59.7% | −797—−59.7% | −652—−45.8% | −546—−36.2% | −470—−29.7% | −503—−60.5% | −438—−53.6% | −376—−43.4% | −329—−36.4% | −293—−31.4% | −259—−27.3% | −233—−50.9% | −207—−42.9% | |
| Shareholders' equity | 1,222—91.6% | 1,222+58.7%91.6% | 1,354+75.4%95.0% | 1,447+75.5%96.0% | 1,516+75.3%95.7% | 770−14.1%92.5% | 772−16.2%94.6% | 825+91.9%95.2% | 865+90.9%95.7% | 897—96.1% | 921—97.3% | 430—94.0% | 453—94.0% | |
| Total liabilities and equity | 1,334—100% | 1,334+60.4%100% | 1,425+74.6%100% | 1,508+74.0%100% | 1,584+75.3%100% | 832−10.8%100% | 816−13.8%100% | 867+89.5%100% | 903+87.4%100% | 933—100% | 947—100% | 457—100% | 482—100% | |
| Shares outstanding | 214—— | 214+17.6%— | 214+23.7%— | 213+23.5%— | 213+23.7%— | 182+6.0%— | 173+0.6%— | 173+23.4%— | 172+23.4%— | 172—— | 172—— | 140—— | 139—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 45+68.5%— | 13+69.8%— | 13+68.3%— | 12+96.7%— | 8.1*+38.4%— | 7.5+24.4%— | 7.5+79.0%— | 5.9+116%— | 5.8*+178%— | 6.0—— | 4.2—— | 2.7—— | 2.1*—— | |
| Cash from operating activities | −271—— | −102*—— | −120*—— | 15—— | −64*—— | −51*—— | −55*—— | −52—— | −36*—— | −20*—— | −26*—— | −34—— | −22*—— | |
| Capital expenditure | — | −3.6*—— | — | −1.2—— | −1.5*—— | −1.6*—— | −0.2*—— | −0.3—— | −0.0*—— | −0.7*—— | −0.4*—— | −0.2—— | −1.2*—— | |
| Cash from investing activities | −316−572%— | 50*—— | 75*+52.2%— | −497−1560%— | 56*+68.9%— | −49*—— | 49*—— | 34+2300%— | 33*—— | −189*—— | −205*—— | 1.4—— | −181*—— | |
| Shares issued | — | — | — | — | — | — | — | — | 0*—— | 0*—— | — | — | — | |
| Cash from financing activities | 706+1114%— | 0.7*−98.7%— | 2.1*+303%— | −1.7−315%— | 705*+114532%— | 56*—— | 0.5*−99.9%— | 0.8+15.2%— | 0.6*−99.8%— | −0.8*—— | 515*—— | 0.7—— | 282*—— | |
| Change in cash | 119—— | −51*—— | −44*—— | −483—— | 697*—— | −44*—— | −5.1*−102%— | −17—— | −2.6*−103%— | −209*—— | 284*—— | −32—— | 79*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Structure Therapeutics Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 9 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office7 subsidiaries | — |
| 🇰🇾 Cayman Islands | 1 subsidiary | — |
| 🇭🇰 Hong Kong | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Structure Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Raymond Stevens, Ph.D. | $8.4 M | $36.2 M | $3.0 M | $268 (peers $135) |
| 2024Chief executive | $5.7 M | $1.7 M | $3.6 M | $104 (peers $101) |
| 2023Chief executive | $7.4 M | $22.1 M | $2.2 M | $157 (peers $102) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Structure Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 2 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
H-1B hiring at Structure Therapeutics Inc.#
1 labor condition applications certified in fiscal 2021 for 1 positions, at a median wage of $300 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Vice President, Cardiopulmonary Clinical DevelopmentClinical Research Coordinators | 1 | $300 K |
Where: South San Francisco, CA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ShouTi Inc.
Discuss Structure Therapeutics Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 9 November 2026automatic update · Nov 9, 2026
Structure Therapeutics Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $145 million.
- Mutual funds: 129 funds hold $951 millionautomatic update · Jul 31, 2026
129 mutual funds in 2 countries hold shares of Structure Therapeutics Inc. worth $951 million, about 9.1% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 49 funds added shares and 51 sold; on balance they bought $15 million. Share splits are not counted as trading.
How Structure Therapeutics Inc. compares in Biotechnology
- Market cap$4.7 B · higher than 89% of 726
- Price / book3.1× · lower than 47% of 534
- FCF yield-4.8% · higher than 73% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Structure Therapeutics Inc.🇺🇸 | $4.7 B | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Structure Therapeutics Inc.? Verify and update this profile — free
Show Structure Therapeutics Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.